The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia

CXCR4(WHIM) somatic mutations are common Waldenstrom's Macroglobulinemia (WM), and are associated with clinical resistance to ibrutinib. We engineered WM cells to express the most common WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis), CXCR(S338X) mutation in WM. Following SDF...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Leukemia 2015-01, Vol.29 (1), p.169-176
Hauptverfasser:	Cao, Y, Hunter, Z R, Liu, X, Xu, L, Yang, G, Chen, J, Patterson, C J, Tsakmaklis, N, Kanan, S, Rodig, S, Castillo, J J, Treon, S P
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Drug Resistance, Neoplasm - genetics Enzyme Activation Extracellular Signal-Regulated MAP Kinases - metabolism Humans Mutation Proto-Oncogene Proteins c-akt - metabolism Pyrazoles - therapeutic use Pyrimidines - therapeutic use Receptors, CXCR4 - genetics Waldenstrom Macroglobulinemia - drug therapy Waldenstrom Macroglobulinemia - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!